Janney Montgomery Scott LLC Has $271,000 Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Janney Montgomery Scott LLC reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 12.3% during the 4th quarter, Holdings Channel reports. The institutional investor owned 6,876 shares of the company’s stock after selling 966 shares during the quarter. Janney Montgomery Scott LLC’s holdings in CRISPR Therapeutics were worth $271,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Sanctuary Advisors LLC bought a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at about $381,000. Exchange Traded Concepts LLC grew its holdings in CRISPR Therapeutics by 22.8% during the third quarter. Exchange Traded Concepts LLC now owns 19,192 shares of the company’s stock worth $902,000 after purchasing an additional 3,563 shares during the period. Vontobel Holding Ltd. increased its position in CRISPR Therapeutics by 3.7% during the third quarter. Vontobel Holding Ltd. now owns 16,957 shares of the company’s stock worth $797,000 after buying an additional 600 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in CRISPR Therapeutics by 56.4% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 13,617 shares of the company’s stock valued at $640,000 after buying an additional 4,909 shares during the period. Finally, nVerses Capital LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $258,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of recent analyst reports. JMP Securities reissued a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, December 20th. Barclays dropped their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Bank of America decreased their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $77.59.

CRISPR Therapeutics Stock Up 0.5 %

Shares of CRISPR Therapeutics stock opened at $39.62 on Wednesday. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10. The company has a market capitalization of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67. The firm’s 50-day moving average price is $42.45 and its two-hundred day moving average price is $46.40.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.08 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.